Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.31 |
| ▸ | CSF1R | P07333 | 2/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | BIRC3 | Q13489 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 4/20 | 0.30 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 3/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1323120 | 1.00 | NTRK1 (0.32) | NTRK1P2RX3CSF1RXIAPBIRC3 | |
| SCHEMBL1323115 | 1.00 | NTRK1 (0.32) | NTRK1P2RX3CSF1RXIAPBIRC3 | |
| SCHEMBL2211967 | 0.90 | KDM4E (0.34) | NTRK1P2RX3CNR2CNR1 | |
| SCHEMBL2211972 | 0.90 | KDM4E (0.34) | NTRK1P2RX3CNR2CNR1 | |
| SCHEMBL380276 | 0.87 | ELANE (0.35) | NTRK1MCHR1 | |
| SCHEMBL12122067 | 0.87 | ELANE (0.35) | NTRK1MCHR1 | |
| SCHEMBL380277 | 0.87 | ELANE (0.35) | NTRK1MCHR1 | |
| SCHEMBL1324444 | 0.85 | MAPT (0.38) | NTRK1MCHR1 | |
| SCHEMBL12122066 | 0.85 | MAPT (0.38) | NTRK1MCHR1 | |
| SCHEMBL1324446 | 0.85 | MAPT (0.38) | NTRK1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-8058272-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-15 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
| US-20100048571-A1 | Organic Compounds | NOVARTIS AG | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048571-A1 | Organic Compounds | XIAP, BAX, MCL1 | NTRK1 4030/4885P2RX3 4244/4885CSF1R 4403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.